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Abstract 42 
(word count 250) 43 
Objective: Statins are reported to have a potential beneficial impact on progression of 44 
osteoarthritis (OA) and on disease activity in rheumatoid arthritis (RA), but existing evidence 45 
is conflicting. Our objective was to examine whether statins associate with reduction of joint 46 
replacement due to OA and RA. 47 
Design: A propensity score matched cohort study. Settings: Electronic health records from 48 
the Clinical Practice Research Datalink, the UK. Participants: We selected people prescribed 49 
statins and people never prescribed statins. Each statin-user was matched to a non-user by 50 
age, gender, practice and propensity score for statin prescription. Main outcome measures: 51 
knee or hip joint replacement overall and specifically because of OA or RA. Measurements: 52 
The association between statins and risk of joint replacement was assessed using Cox 53 
proportional hazard regression. Statin exposure was categorised according to the potency of 54 
reducing LDL as low (21-28%) medium (32-38%) or high (42-55%) intensity. 55 
Results: 178,467 statin-users were matched with 178,467 non-users by age, gender and 56 
propensity score. Overall, statin use was not associated with reduced risk of knee or hip 57 
replacement (HR 0.99, 95% CI 0.97 to 1.03), unless prescribed at high strength (0.86, 0.75 to 58 
0.98). The reduced risk was only observed for joint replacement due to RA (0.77, 0.63 to 0.94) 59 
but not OA (0.97, 0.94 to 1.01).     60 
Conclusions: Statins at high intensity may reduce the risk of hip or knee replacement.  This 61 
effect may be RA specific. Further studies to investigate mechanisms of risk reduction and the 62 
impact in people with RA are warranted. 63 
 64 
Registration  65 
The study protocol was approved by the Independent Scientific Advisory Committee (ISAC) 66 
for Medicines and Healthcare Products Regulatory Agency (MHRA) (protocol 12_020R2AR).  67 
Primary Funding Source  68 
National Institute for Health Research and National Natural Science Foundation of China.   69 
Key Messages 70 
• Statins are routinely used in the treatment of cardiovascular diseases, however also 71 
might be beneficial for other conditions.  72 
• In this study statins at high dose showed reduced risk of hip or knee replacement, 73 
particularly in people with rheumatoid arthritis.  74 
• Further studies to investigate mechanisms of risk reduction and the impact in people 75 
with RA are warranted. 76 
Introduction 77 
Joint replacement is one of the major economic burdens for healthcare systems worldwide[1-78 
3]. The number of joint replacements performed each year have risen dramatically[4, 5] and 79 
are set to continue rising with the aging population[6]. Waiting-list audits demonstrate that 80 
current surgical provision does not meet healthcare needs[7]. Approximately 90% of all joint 81 
replacements are performed for osteoarthritis (OA)[6].  82 
Statins are lipid-lowering drugs recommended for primary and secondary prevention of 83 
cardiovascular disease (CVD)[8]. Statins lower circulating level of low-density lipoproteins, 84 
and have other anti-inflammatory and immune-modulating effects[9-14] that have prompted 85 
studies to examine the potential role of statins as structure-modifying treatments for OA[15]. 86 
However, the possible effect of statins on development and progression of OA remains 87 
unclear. One of the earliest studies by Beattie et al[16] reported an increased rate of 88 
radiographic hip OA in elderly women. A study by Kadam et al[17] found an association 89 
between higher statin dose (the 4th quartile) and reduction in incident OA in people with 90 
existing CVD. Statin use associated with radiographic progression of knee OA but not hip OA 91 
in a study by Clockaerts et al[18]. However, more recent large studies have not confirmed 92 
these findings. For example, statins were associated with radiographic worsening of knee OA 93 
over 3 years in a study by Eymard et al[19] but a UK cohort study did not find any association 94 
between statin use and incident hand OA[20]. Pooled results from four large Swedish 95 
population-based cohorts showed no association between statin use and consultation or 96 
surgery for OA of the hip or knee[21]. In the Osteoarthritis Initiative Cohort statin use was not 97 
associated with lower risk of pain worsening, incident radiographic knee OA or radiographic 98 
symptomatic knee OA unless taken for more than 5 years[22]. A recent study in the Clinical 99 
Practice Research Datalink  (CPRD) found that statin therapy initiated up to 5 years following 100 
total hip/knee replacement may reduce the risk of revision arthroplasty[23].  Some evidence 101 
supports a potential beneficial impact of statins on disease activity, attributable to their anti-102 
inflammatory and immunomodulatory properties in rheumatoid arthritis (RA)[24-27]. However, 103 
whether statins have different effects on joint replacements due to OA and RA has not been 104 
examined.  105 
We therefore undertook the present study using a large UK-wide national primary care 106 
database to investigate the association between statins and risk of joint replacement due to  107 
OA and RA.  108 
Methods 109 
Study design 110 
This was a propensity score matched cohort study. 111 
Participants 112 
The CPRD is a large, longitudinal population-based, primary care database that includes data 113 
on demographics, symptoms, tests, diagnoses, prescriptions and referrals to secondary care 114 
routinely collected by UK general practitioners (GPs). By July 2017, it covered 718 GP 115 
practices in England, Scotland, Wales, and Northern Ireland with anonymised health data on 116 
over 17 million people (26% of the total UK population)[28]. The accuracy and completeness 117 
of the CPRD has been validated by previous studies[29] and many studies have investigated 118 
effects of statin on various conditions[30-33]. The study protocol was approved by the 119 
Independent Scientific Advisory Committee (ISAC) for Medicines and Healthcare Products 120 
Regulatory Agency (MHRA) (protocol 12_020R2AR). 121 
We identified a cohort of patients aged 40 and over, registered with up-to-standard GP 122 
practices (i.e. practices that met standardised quality criteria based on the continuity of 123 
recording and the number of recorded deaths) for more than 12 months from 1 January 1987 124 
to 31 July 2017. Statin-users were defined as people who were ever prescribed a statin (two 125 
or more prescriptions).   Non-users were defined as people who had never been prescribed 126 
statins during the period of current registration. 127 
For statin users the index date was defined as the date of first statin prescription. Non-users 128 
were assigned an index date of their matched statin-users (pairs were matched by year of 129 
birth, gender and practice). Patients were followed up from the index date until first joint 130 
replacement, death, deregistration, or end of follow-up (31 July 2017) whichever came first.  131 
A flow chart of the selected main cohort included is shown in Figure 1. The main cohort was 132 
further refined for a cohort excluding those with existing cardiovascular disease (CVD) in order 133 
to estimate the risk of joint replacement in people without CVD as defined by the NICE 134 
guidelines[34], i.e., using statin as a primary prevention.  135 
Exclusion criteria were: invalid age or gender records; invalid joint replacement date; joint 136 
replacement prior to the first prescription of statin; joint replacement due to hip fracture or 137 
infection; revision surgery without a record of a primary joint replacement; invalid statin 138 
prescription data (e.g.  if the number of tablets in prescription prescribed exceeded 600 or the 139 
daily dose exceeded the maximum daily dose for this drug); statin-users who received a single 140 
statin prescription only; statin-users prescribed cerivastatin (withdrawn from the market in 141 
2001 due to adverse effects); and statin-users with prescription gaps of more than 90 days 142 
(i.e. discontinuation).  143 
Exposure 144 
The first statin prescription after a statin-free period of ≥12 months (to prevent prevalent user 145 
bias) was identified using drug codes in CPRD[35]. We prioritised UK approved statins that 146 
were available for prescription, including simvastatin, atorvastatin, fluvastatin, rosuvastatin, 147 
and pravastatin (simvastatin 10 mg is also available over-the-counter). Statins were 148 
categorised as low intensity (21-28% reduction in low-density lipoprotein), medium intensity 149 
(32-38%) and high intensity (42-55%) according to their lipid lowering potency[36] (Appendix 150 
1). Median statin intensity was calculated for each year of intake and for the total duration of 151 
statin exposure.  152 
Total duration of statin exposure was defined as the continuous use of statin, i.e., no 153 
discontinuation of more than 90 days between prescriptions during the follow-up period.  This 154 
90-day exposure window has been used in previous studies based on routinely collected data 155 
in primary care[32, 33, 37].  156 
Percentage of days covered (PDC) by statins per year was estimated as the number of 157 
prescriptions multiplied by days of each prescription (considering number of tablets per day or 158 
if not specified assuming a dosage of one tablet per day) divided by 365. Switching between 159 
statins or to fixed combinations was regarded as a continuation of therapy. 160 
We accounted for overlapping tablet days assuming that the patient had finished the current 161 
prescription before starting the refill prescription as shown in Appendix 2 (e.g. the patient was 162 
credited for the surplus statin from overlapping refills)[38].   163 
Outcomes 164 
The primary outcome was joint replacement defined as at least one record of total or partial 165 
knee joint replacement (KJR) or hip joint replacement (HJR) according to the standard clinical 166 
terminology system used in General Practice in the United Kingdom i.e. Read codes.  Read 167 
codes for KJR and HJR are provided in Appendix 3. If a person had HJR plus KJR, the earlier 168 
event was chosen for any joint replacement. We also examined: [1] site-specific (hip or 169 
knee) joint replacement; [2] joint replacement due to OA (Read codes included hip OA, 170 
knee OA, generalised OA, other joint OA); [3] joint replacement in people with RA.   171 
OA was defined as present if at least one record of hip OA, knee OA, generalised OA, and 172 
OA of other joints was identified during follow-up.   173 
RA was defined as present if either of two definitions was met, specifically: (1) at least one 174 
diagnostic Read code for RA (any group) and at least one appropriate prescription of a 175 
DMARD with no alternative indication for the DMARD; or (2) two or more diagnostic Read 176 
codes for RA (on different dates) and at least one RA code in group 1 or group 2 with no 177 
alternative diagnosis after the final RA code (Appendix 4) [39, 40].  178 
Secondary outcomes: [1] joint replacement in people without CVD i.e. focusing on statin 179 
use for primary prevention of CVD. 180 
Covariates 181 
Patient demographics (e.g. age, sex, practice), comorbidities and relevant medications were 182 
identified as covariates. Body mass-index was not included because it caused a large number 183 
of missing data, especially in controls. All comorbidities, including those diagnoses used as 184 
alternative indications for DMARDS or alternative diagnosis for OA and peripheral joint pain, 185 
are defined in Appendix 5. CVD included diseases of the heart and blood vessels caused by 186 
atherosclerosis including heart attack, myocardial infarction, coronary or ischaemic heart 187 
disease and atherosclerosis (NICE guidelines). 188 
 189 
Statistical analysis 190 
Propensity score 191 
Each statin-user was matched with non-user by age, gender, practice, and propensity score 192 
(PS). We estimated a PS (i.e. probability of being prescribed statin) for each statin user and 193 
non-user using multivariable logistic regression.  194 
PS model for the main cohort included age, gender, lifestyle factors (smoking, alcohol 195 
dependence), RA (yes/no), RA duration in years, OA (yes/no), OA duration in years, Charlson 196 
comorbidity index and individual comorbidities to reduce residual confounding (diabetes 197 
mellitus, hypertension, cardiovascular disease, ischaemic stroke and other thromboembolic 198 
diseases, peripheral pain, peripheral vascular disease, atrial fibrillation, congestive heart 199 
disease, renal disease, valvular heart disease), and other medications used (nitrates, anti-200 
platelets, diuretics, β-blockers, calcium-channel blockers, angiotensin-converting enzyme 201 
inhibitors, angiotensin II receptor antagonists, DMARDs, oral corticosteroids).   202 
For the sub-cohort (Figure 1) we estimated subgroup-specific PS and re-matched 203 
individuals[41]. PS model for people without CVD at baseline included the same set of co-204 
variates as in the PS model for main analysis except for CVD. 205 
PS matching was performed using the “greedy” matching algorithm[42] where a set of X cases 206 
was matched to a set of Y controls in a set of X decisions, excluding those who could not be 207 
matched. PS distribution before and after matching for the main cohort is shown in Appendix 208 
6. Before PS matching we trimmed at the extreme ends of the PS tail (below the 5th and above 209 
the 95th percentile)[43]. Covariate balance was assessed with standardised mean differences 210 
(SMD)[44]. Post-matching SMD <0.1 indicated a good covariate balance between groups[44, 211 
45]. SMD is a validated method to assess whether the PS scores are comparable between 212 
treated and untreated groups. SMD is preferable over significance testing (i.e. p-value) which 213 
is influenced by sample size, and over the c-statistic or area under the receiver operating 214 
characteristic (ROC) curve[45].  215 
Time to event analysis 216 
Cox proportional hazards regression was used to examine the hazard ratio (HR) and 95% 217 
confidence interval (CI) between statin users and non-users. For our primary analysis we 218 
estimated: 219 
• Non-PS matched  HR using multivariable Cox regression, adjusting for all covariates 220 
including  age, gender, lifestyle factors (smoking, alcohol dependence), RA (plus 221 
duration in years), OA (plus duration in years), Charlson comorbidity index (Appendix 222 
7), comorbidities (diabetes mellitus, hypertension, cardiovascular disease, ischaemic 223 
stroke and other thromboembolic diseases, peripheral pain, peripheral vascular 224 
disease, atrial fibrillation, congestive heart disease, renal disease, valvular heart 225 
disease), other medication used (nitrates, anti-platelets, diuretics, β-blockers, calcium-226 
channel blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor 227 
antagonists, DMARDs, oral corticosteroids).   228 
• PS matched HR using  Cox regression  stratified on matched sets with robust standard 229 
errors to account for “cluster effect” within matched pairs[42, 46]. 230 
Dose-response analysis was performed using linear trends for effect of statin intensity (0 for 231 
non-users, 1 for low, 2 for medium and 3 for high intensity).   232 
In addition, competing risk of death was adjusted using the proportional sub-distribution 233 
hazard regression [47-49].  This was because if a person died before an outcome of interest, 234 
it would challenge the assessment of that outcome.  235 
 236 
All analyses were performed using SAS statistical software version 9.4  237 
Role of the Funding Source 238 
The funding source had no role in: the design or conduct of the study; the collection, analysis, 239 
or interpretation of the data; or the writing of the report. The corresponding authors had full 240 
access to all data in the study and had final responsibility for the decision to submit the 241 
manuscript for publication.  242 
Results 243 
Cohort description. In total, 3,981,838 individuals met our inclusion criteria, of whom 706,943 244 
were statins-users and 178,467 were successfully PS matched to the same number of non-245 
users (PS distribution before and after matching is shown in Appendix 6). After PS-matching, 246 
all covariates were balanced between the two groups (Table 1).  The number of patients at 247 
risk of having joint replacement in each year of follow-up is shown in Appendix 8. The mean 248 
age of the matched cohort was 62 (SD ~11, range 40-86) years and 52% were women (Table 249 
1). Mean duration of follow-up was 6.88 (SD 3.98) for statin-users and 6.25 years (SD 3.82) 250 
for non-users. The maximum period of follow up was 28 years in both groups.  251 
Statin prescribing. Most statin-users in the PS-matched cohort started treatment with 252 
medium intensity statins (73%) and had good adherence (PDC≥80) at baseline and during the 253 
first year of follow-up (75% and 63% respectively). 26% of statin-users discontinued treatment 254 
during the first 2 years (Table 2).  255 
Joint replacement. In non-PS matched analysis statin-users had higher probability of having 256 
any joint replacement compared to non-users (HR 1.13, 95% CI 1.10 to 1.16). However, in the 257 
PS-matched cohort joint replacement was not associated with statins (0.99, 0.97 to 1.03)) 258 
(Table 3). Additional adjustment for the competing risk of death in the PS-matched cohort 259 
provided similar results (1.02, 0.98 to 1.05). 260 
In the subgroup analysis, there were no relationships between statins and KJR or HJR, or joint 261 
replacement due to OA (Table 3). However, statin-users with RA were less likely to undergo 262 
joint replacement (0.77, 0.63 to 0.94).  263 
Further analysis in the PS-matched cohort demonstrated an overall trend of dose response 264 
effect but this was only significant for any joint replacement (p for trend 0.0244) and KJR (p 265 
for trend 0.0210) (Figure 2, Appendix 9).  However, comparing to non-users, statins at the 266 
high intensity had lower risk of any joint replacement (HR 0.86, 95%CI 0.75 to 0.98), joint 267 
replacement due to RA (0.10, 0.02 to 0.65) and joint replacement due to OA (0.79, 0.68 to 268 
0.92).  269 
Among people without any diagnosed CVD at baseline (i.e. primary prevention) statin-users 270 
had a marginally lower risk of joint replacement compared to non-users (0.96, 0.93 to 1.00).  271 
Discussion 272 
The key findings of this population-based cohort study are: [1] statin use was associated with 273 
reduced joint replacement due to RA but not OA; [2]  high intensity statin was associated with 274 
reduced joint replacement due to both RA and OA; and [3] a dose response relationship was 275 
observed for any joint replacement and knee joint replacement outcomes.  276 
 277 
The main results of this study are consistent with results from four large Swedish population-278 
based cohorts [21] that did not find any association between statin use and joint replacement 279 
due to OA. We used joint replacement as the primary outcome because it is a hard outcome 280 
and well coded in CPRD[6].  Using this outcome without the selection of index disease (OA in 281 
this case) helps to avoid “index event bias”[50]. We used the PS matched method to minimize  282 
“confounding by indication” – an important issue with observational studies examining 283 
therapeutic effects[51]. The balanced PS between the groups and the difference between non-284 
PS and PS-matched results suggest that confounding by indication was kept to the minimum 285 
according to the known factors.   The reduction of HR from non-PS matched to the PS-286 
matched methods suggests that the direction of the confounding by indication is towards a 287 
positive (HR>1), not negative association (HR<1). This means that if a positive association is 288 
observed, it is likely to be biased/inflated, whereas if a negative association is observed it is 289 
likely to be true and to become even more negative should this confounding be fully controlled. 290 
This is in line with our knowledge that both OA and RA are associated with CV events, hence 291 
patients with OA or RA are more likely to be given statins than those without these conditions. 292 
In addition, our further analysis in people without CVD shows that statins were negatively 293 
associated with joint replacement although it was just marginal (p=0.05). This suggests that 294 
the PS calculation for joint replacement outcome is justified and the protective effect of statin 295 
on joint replacement may be independent from CVD. Furthermore, we controlled for other 296 
potential biases. For example, we used the incident statin users in this analysis to avoid “bias 297 
of prevalent users”[35]. If we used prevalent exposure, we were unable to define the starting 298 
point of the exposure, hence unable to measure time to event outcome.  We also accounted 299 
for “immortal time bias” by matching index dates between statin-users and non-users[52].  300 
  301 
It is well-established that people with RA have an increased CV risk as a result of  complex 302 
interaction between traditional risk factors (dyslipidaemia, insulin resistance, arterial 303 
hypertension, obesity, smoking) and chronic auto-immune inflammation [25]. Statin treatment 304 
has been reported to reduce CV risk in RA individuals through its angio-protective, lipid-305 
lowering and anti-oxidative effects[24, 26]. Moreover, several studies report that statins may 306 
influence the inflammatory process and disease activity[24, 27]. Our findings on decreased risk 307 
of joint replacement due to RA in statin-users could suggest that statins reduce subsequent 308 
joint damage and slow the rate of progression to surgery.  We hypothesize that if statins work 309 
for both cardiovascular events and arthritis-related joint replacement, this might lead to some 310 
changes in treatment recommendations. 311 
 312 
There are potential limitations to this study. Firstly, we could only use data and variables that 313 
are recorded in the CPRD.  There are many variables that may influence the balance between 314 
statin users and non-users hence confounding by indication cannot be fully removed (e.g. 315 
BMI).  However, from the PS-matched and non PS-matched analyses, we understood the 316 
direction of this confounding, which helps us to adequately interpret the findings with negative 317 
association. Secondly, OA records in the CPRD reflect physician-diagnosed OA and are likely 318 
to follow NICE criteria for clinical OA that focus on symptomatic cases alone[53]. Also we 319 
could not account for any delay between first symptoms and the diagnosis of OA/RA in primary 320 
care. This was one of the reasons why we used joint replacement as our primary outcomes 321 
as this is less prone to misclassification bias. Thirdly, our definition of joint replacement due to 322 
OA only included hip and knee OA so the results cannot be generalised to other joints affected 323 
by OA. Fourthly, cholesterol testing is not routine in the UK general practice, therefore serum 324 
cholesterol was not included in the propensity score model. Fifthly, we did not consider 325 
variation in statin prescriptions during follow-up, but used a simple continuous measure (no 326 
gaps more than 90 days) that may lead to potential imbalance in terms of exposure between 327 
statin users and non-users. Moreover, users of high intensity statins particularly in RA-group 328 
were underrepresented in our analysis (Appendix 9) and therefore, a well-designed study with 329 
balanced groups is needed to confirm observed dose-response effect.  Finally, we were able 330 
to obtain good covariate balance between groups by using propensity score matching, 331 
however, unknown confounding factors and their potential bias to the study cannot be fully 332 
eliminated. 333 
Conclusion 334 
In summary, statins may reduce the risk of joint replacement, especially when given at high 335 
strength and in people with RA. The evidence in knee replacement is stronger than that in hip 336 
replacement. Further studies to investigate mechanisms of joint replacement risk reduction in 337 
people with RA are warranted.  338 
Table 1. Baseline characteristics  339 
 
 
Before PS-matching PS-matched 
 










Index year, n (%)        
1989-1999  30,475 (5.42) 27,397 (4.87)  7,286 (4.08) 7,754 (4.34)  















49,805 (27.91)  




Age in years, mean (SD)  63.03 (11.02) 63.42 (11.11) 0.036 61.91 (10.64) 62.00 (11.74) 0.007 
Women, n (%)  266,324 
(47.34) 






95,343 (53.42) 0.063 






96,755 (54.21) 0.029 
Alcohol dependence, n (%)  522 (0.09) 538 (0.10)   149 (0.08) 232 (0.13)  
RA, n (%)  5,702 (1.01) 4,493 (0.80) 0.023 1,906 (1.07) 2,036 (1.14) 0.007 
Duration (years), mean (SD)  0.09 (1.12) 0.07 (1.00) 0.074 0.09 (1.13) 0.10 (1.21) 0.025 
Any OA, n (%)  97,800 (17.39) 74,482 (13.24) 0.115 28,387 
(15.91) 
30,626 (17.16) 0.034 
Duration (years), mean (SD)  1.24 (3.66) 0.97 (3.35) 0.077 1.12 (3.50) 1.19 (3.59) 0.019 










72,305 (40.51) 0.085 
Charlson Index, mean (SD)  0.89 (1.82) 0.76 (1.79) 0.074 0.80 (1.77) 0.85 (1.83) 0.025 
Renal, n (%)  31,627 (5.62) 15,139 (2.69) 0.147 8,582 (4.81) 8,302 (4.65) 0.007 
Coronary, n (%)  123,781 
(22.00) 
15,376 (2.73) 0.612 7,576 (4.25) 6,907 (3.87) 0.019 
Cerebrovascular disease, n 
(%) 
 48,903 (8.69) 9 291 (1.65) 0.322 5,297 (2.97) 4,230 (2.37) 0.037 
Peripheral vascular disease, 
n (%) 
 23,586 (4.19) 4,908 (0.87) 0.213 2,838 (1.59) 2,295 (1.29) 0.026 
Carotid, n (%)  2,106 (0.37) 210 (0.04) 0.074 107 (0.06) 55 (0.03) 0.014 
Atrial fibrillation, n (%)  27,506 (4.89) 13,601 (2.42) 0.132 7,012 (3.93) 6,726 (3.77) 0.008 
Valvular heart disease, n 
(%) 
 1,439 (0.26) 624 (0.11) 0.034 364 (0.20) 350 (0.20) 0.002 






73,848 (41.38) 0.030 
Diabetes, n (%)        
Without complications  101,978 
(18.13) 
10,083 (1.79) 0.666 4,325 (2.42) 2,785 (1.56) 0.093 
With complications  16,876 (3.00) 2,308 (0.41)  1,474 (0.83) 778 (0.44)   
Congestive heart disease, n 
(%)  
 17,539 (3.12) 6,294 (1.12) 0.139 3,112 (1.74) 2,576 (1.44) 0.024 




Nitrates  87,410 (15.54) 6,441 (1.15) 0.539 2,645 (1.48) 1,895 (1.06) 0.038 
Diuretics  182,956 
(32.52) 
73,073 (12.99) 0.955 43,448 
(24.35) 
44,962 (25.19) 0.020 
Anti-platelets  244,934 
(43.54) 
35,241 (6.26) 0.955 19,129 
(10.72) 
16,214 (9.09) 0.055 





43,265 (7.69) 0.721 28,112 
(15.75) 
27,586 (15.46) 0.008 
AGT antagonists  52,939 (9.41) 16,843 (2.99) 0.268 11,386 (6.38) 11,378 (6.38) 0.001 
Β-blockers  170,622 
(30.33) 
42,830 (7.61) 0.479 25,180 
(14.11) 
27,614 (15.47) 0.038 
Note: PS – propensity score, SMD – standardised mean difference, SD – standard deviation, DMARDs – disease-modifying 340 
antirheumatic drugs, AGT antagonists - angiotensin II receptor antagonists. 341 
 342 
  343 
Table 2. Statins characteristics.  344 
Variable Measure 
N  178,467 
Intensity at start, n (%)  
Low 32,652 (18.30) 
Medium 130,980 (73.39) 
High 14,835 (8.31) 
Total exposure period, days, mean (SD) 2,024 (1566) 
Total exposure period, years, n (%)  
Less than 2 years  46,664 (26.15) 
3-4 years 30,679 (17.19) 
5-6 years 27,407 (15.36) 
7-8 years 23,744 (13.30) 
9-10 years 19,587 (10.98) 
>10 years 30,386 (17.03) 
Baseline PDC, mean (SD) 0.85 (0.24) 
Baseline PDC >=80%, n (%) 133,664 (74.90) 
Year 1 PDC (>2 years intake), mean (SD)  0.76 (0.25) 
Year 1 PDC>=80% (>2 years intake), n (%) 88,700 (62.48) 
Note: SD – standard deviation, PDC – proportion of days covered.  345 
Table 3. Relation of statin use to joint replacement surgery  346 
 


















Any joint replacement        
Statin-users 21,430 3,989,753 7.09 (4.07) 1.13 (1.10 to 1.16) 6,490 1,229,427 6.88 (3.98) 0.99 (0.97 to 1.03) 
Non-users 15,910 3,607,011 6.41 (3.90) 1 (reference) 5,691 1,115,447 6.25 (3.82) 1 (reference) 
Joint replacement due to OA       
Statin-users 16,263 4,013,272 7.14 (4.08) 1.11 (1.08 to 1.15) 4,901 1,236,347 6.92 (3.99) 0.97 (0.94 to 1.01) 
Non-users 11,821 3,623,933 6.44 (3.91) 1 (reference) 4,378 1,120,856 6.28 (3.83) 1 (reference) 
Joint replacement due to RA       
Statin-users 549 4,086,522 7.27 (4.12)  0.90 (0.77 to 1.05) 173 1,256,995 7.04 (4.03) 0.77 (0.63 to 0.94) 
Non-users 431 3,674,882 6.53 (3.95) 1 (reference) 191 1,139,272 6.39 (3.88) 1 (reference) 
Hip joint replacement        
Statin-users 9,894 4,044,099 7.19 (4.10) 1.08 (1.05 to 1.13) 3,104 1,244,379 6.97 (4.01) 0.98 (0.93 to 1.03) 
Non-users 8,265 3,641,043 6.47 (3.92) 1 (reference) 2,783 1,128,209 6.32 (3.85) 1 (reference) 
Knee joint 
replacement 
       
Statin-users 12,444 4,031,130 7.17 (4.09) 1.17 (1.13 to 1.21) 3,675 1,241,714 6.95 (3.99) 1.00 (0.96 to 1.05) 
Non-users 8,350 3,640,147 6.47 (3.92) 1 (reference) 3,165 1,126,343 6.31 (3.85) 1 (reference) 
 347 
Note: PS – propensity score, JR – joint replacement, OA – osteoarthritis, RA – rheumatoid arthritis, SD- standard deviation, 348 
hazard ratios (HR) with 95% confidence intervals (CI) 349 
* - Multivariate Cox regression model adjusted for covariates included in the PS-model (age, gender, smoking, alcohol 350 
consumption, RA (plus duration in years), OA (plus duration in years), Charlson comorbidity index, comorbidities (diabetes 351 
mellitus, hypertension, cardiovascular disease, ischaemic stroke and other thromboembolic diseases, peripheral pain, 352 
peripheral vascular disease, atrial fibrillation, congestive heart disease, renal disease, valvular heart disease), other medication 353 
used (nitrates, antiplatelets, diuretics, β-blockers, calcium-channel blockers, angiotensin-converting enzyme inhibitors, 354 
angiotensin II receptor antagonists, DMARDs, oral corticosteroids) 355 
** - Cox regression model stratified on PS matched sets with robust standard errors to account for “cluster effect” and 356 
subpopulation differences 357 
  358 
Figure 1. Flow chart of cohort  359 
 360 
  361 
Figure 2. Statin use and joint replacement surgery: dose-response analysis 362 
 363 
Note: Dose-response analysis was performed using Cox regression and compared people taking low, 364 
medium and high intensity statins with non-users (reference category). Statin exposure was 365 
categorised as low (21-28% reduction in low-density lipoprotein cholesterol), medium (32-38%) and 366 
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